Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Feb 8, 2023

Provention Bio to Present at the SVB Securities Global Biopharma Conference
Feb 3, 2023

Provention Bio Announces the Grant of Inducement Awards
- Photos 1
Feb 2, 2023

Provention Bio Announces Closing of Second Tranche with Hercules Capital to Support U.S. Commercial Launch of TZIELD®
Jan 25, 2023

NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
Jan 25, 2023

FDA approves expanded label of Enjaymo® (sutimlimab-jome) to include long-term safety and efficacy for people with cold agglutinin disease
Jan 18, 2023

Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
Jan 17, 2023

FDA approves Adacel® for immunization during pregnancy to help protect young infants against pertussis
Jan 6, 2023

Provention Bio Announces the Grant of Inducement Awards
Jan 5, 2023

Provention Bio Announces Appointment of Rita Jain, M.D., to Board of Directors
Dec 21, 2022

Positive Dupixent® (dupilumab) Phase 3 results in adults and adolescents with eosinophilic esophagitis published in the New England Journal of Medicine

Dupixent 300 mg weekly showed significant histological disease remission and improvement in symptoms of the disease compared to placebo
Dec 2, 2022

Provention Bio Announces the Grant of Inducement Awards
Dec 2, 2022

Sanofi to showcase new data from oncology portfolio spanning marketed products and investigational compounds at ASH 2022

Four Sarclisa® (isatuximab-irfc) oral presentations and 11 posters featuring cutting-edge investigational and marketed therapies to be presented
Nov 30, 2022

Sanofi to present new clinical data reinforcing novel therapies across rare blood disorders at ASH 2022
Nov 17, 2022

TZIELD™ (teplizumab-mzwv) approved by FDA as the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D
Nov 4, 2022

Provention Bio Announces the Grant of Inducement Awards
Nov 3, 2022

Provention Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 13, 2022

Provention Bio to Report Third Quarter 2022 Financial Results on November 3, 2022
Oct 7, 2022

Provention Bio Announces the Grant of Inducement Awards
Oct 6, 2022

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes
Oct 6, 2022

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals
Sep 28, 2022

Dupixent® (dupilumab) approved by FDA as the first and only treatment indicated for prurigo nodularis

Dupixent significantly reduced itch and skin lesions compared to placebo in direct-to-Phase 3 program consisting of two pivotal trials
Sep 19, 2022

Provention Bio Announces Senior Leadership Addition
Sep 8, 2022

Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Sep 6, 2022

Provention Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Sep 2, 2022

Provention Bio Announces the Grant of Inducement Awards

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.